Evercore ISI analyst Elizabeth Anderson resumed coverage of AmerisourceBergen with an Outperform rating and $185 price target. The company’s core drug distribution business and "formidable" specialty operations should generate mid-to-high single digit operating profit growth and double digit EPS growth over the medium-term, the firm tells investors. Evercore sees upside to valuation as visibility improves post-COVID, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABC:
- AmerisourceBergen to change name to Cencora
- AmerisourceBergen plans to change name to Cencora
- AmerisourceBergen price target raised to $190 from $170 at Argus
- AmerisourceBergen price target raised to $199 from $195 at Baird
- Billionaire Leon Cooperman Says the Bear Market Is Expected to Continue in 2023 — Here Are 2 ‘Safe Haven’ Stocks That Analysts Like